An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated November 6, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on Hexarelin; the papers are listed at the end. Research summary, not a recommendation.
What it is
Hexarelin is a synthetic six-amino-acid peptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) from the growth hormone-releasing peptide (GHRP) family developed in the early 1990s. It is a stabilized analog of GHRP-6 designed to resist breakdown and release growth hormone when given by injection, nasally or by mouth. It was studied extensively in the 1990s but never approved as a drug.
How it works
Hexarelin activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor used by the stomach hormone ghrelin, on pituitary and hypothalamic cells. This triggers a pulse of growth hormone release that is larger than the body's normal pulses, and it also raises cortisol and prolactin through hypothalamic vasopressin signaling. Separately, hexarelin binds CD36 on heart and blood vessel cells, which is the proposed route for the heart-protective effects seen in animals. Repeated dosing in humans led to partial loss of the growth hormone response over time.
What it has been studied for
Growth hormone release in healthy adults and children (dose-response studies)
Diagnostic testing of growth hormone deficiency
Cardioprotection after heart attack and in heart failure (animal models)
Metabolic effects in obesity models (animal)
Strength of the evidence
Early human studiesSingle-dose and short-course human studies from the 1990s established GH release and hormonal side effects; no phase 3 trials and no approved indication exist.
What the literature reports on safety
Human studies reported transient flushing, sweating and sleepiness, with dose-dependent rises in cortisol and prolactin alongside growth hormone. Chronic use produced a gradual blunting of the growth hormone response. It is unapproved, listed as prohibited by the World Anti-Doping Agency, and long-term safety data are lacking.
Animal study · Mao Y, Tokudome T, et al. · Peptides (2014) · PMID 24747279
A single oral dose given after induced heart attack in mice improved later heart function.
Sources checked: PubMed/PMC (E-utilities), written 2026-11-06.
Hunter Williams, in his own words
Figures quoted, not recommended. These are Hunter Williams' descriptions, not an agreed treatment protocol.
1 quotations from his library pages, each with its source. A quote marked with a product name is about a blend that includes Hexarelin.
What he says it is for
“On paper, hexarelin has huge GH release potential. In practice, it raises prolactin and cortisol significantly, and you build a tolerance fast. Maybe four weeks max before it stops working. The use case is short-term injury recovery.”
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about Hexarelin? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.